If you don't qualify as an accredited investor, the blunt reality is this: you cannot directly purchase SpaceX, OpenAI, Anthropic, or Databricks shares before their IPOs. The secondary market platforms that facilitate pre-IPO trades — Hiive, Forge, EquityZen — are accredited-only. SPVs that pool investor capital for pre-IPO purchases are also restricted to accredited investors under Regulation D.

But "can't buy shares directly" and "can't get any exposure" are not the same thing. There are legitimate, regulated vehicles that give non-accredited investors real economic exposure to the companies in the 2026 IPO pipeline — some of which are accessible through standard brokerage accounts. This guide explains what's actually available, what the tradeoffs are, and what to watch out for.

Option 1: Destiny Tech100 (DXYZ) — Exchange-Traded Pre-IPO Exposure

Destiny Tech100 is a NYSE-listed closed-end fund that holds equity positions in SpaceX, OpenAI, Anthropic, Stripe, Databricks, and other late-stage private companies. Because it trades on the NYSE, any investor with a standard brokerage account can buy DXYZ — no accreditation required, no minimum investment beyond the share price.

What it holds: A portfolio of approximately 100 late-stage private technology companies. As of 2026, the largest positions include SpaceX, OpenAI, Anthropic, Stripe, and Databricks — exactly the names driving search volume in this market.

Why it works for non-accredited investors: As a listed closed-end fund, DXYZ is a registered investment company under the Investment Company Act. SEC registration makes its shares available to retail investors without Reg D restrictions.

The NAV premium problem: This is the most important risk to understand. DXYZ has consistently traded at a significant premium to its Net Asset Value — often 50–200% above the underlying holdings' fair market value. This means you may be paying $2 for every $1 of actual SpaceX or OpenAI exposure.

Why the premium exists: Demand from non-accredited investors who have no other direct path to these companies creates a scarcity premium. DXYZ is the only exchange-traded vehicle with meaningful SpaceX, OpenAI, and Anthropic exposure. That scarcity gets priced into the stock.

What to do about it: Monitor the DXYZ premium to NAV before buying. The premium can compress significantly — particularly when a portfolio company IPOs and accredited investors gain direct access, reducing DXYZ's scarcity value. Buying at a 200% premium to NAV when an IPO is imminent is a different risk profile than buying at a 50% premium with a 2-year horizon.

Current availability: Ticker DXYZ on NYSE. Available through Fidelity, Schwab, Robinhood, and all major brokerages.

Option 2: ARK Venture Fund (ARKVX) — Interval Fund with Lower Friction

The ARK Venture Fund is a semi-liquid interval fund managed by ARK Invest. It holds a portfolio of private and public high-growth companies including SpaceX, OpenAI, Anthropic, and Databricks — acquired through board-authorized channels, not unauthorized secondaries.

Unlike DXYZ (which trades on an exchange), ARKVX is an interval fund — meaning you subscribe and redeem through the fund manager rather than buying and selling on an exchange. The tradeoff: ARKVX is priced at NAV rather than at a market premium. You're paying fair value for the underlying exposure, not a scarcity premium.

Availability: ARKVX is distributed through several platforms including Fidelity and some RIA-managed account platforms. Minimum investment is as low as $500 on certain distribution channels.

Accreditation note: ARK Venture Fund technically requires accredited investor status, but many distribution platforms apply their own eligibility criteria. Check the specific platform through which you're accessing ARKVX — some make it available to non-accredited investors through managed account wrappers.

Liquidity: Quarterly redemption windows subject to gates. Not daily liquidity. Plan to hold for 6–18 months minimum.

Fee: 2.75% annual management fee with no carried interest. For a long-duration hold, this is a meaningful cost — though lower than most SPV structures when carry is factored in.

Option 3: Fundrise Innovation Fund — Lowest Minimum, Broadest Retail Access

The Fundrise Innovation Fund is a retail-accessible vehicle (minimum $10 investment) offering diversified exposure to a portfolio of private technology companies. While it may not hold the specific names at the same concentration as ARKVX or DXYZ, it provides genuine private market exposure to growth-stage companies that include some of the names driving the 2026 IPO excitement.

Best for: Retail investors who want to get started with private market investing at minimal capital commitment. The $10 minimum is genuinely one of the lowest available for any alternative investment vehicle.

Limitation: Portfolio composition is broad and may not deliver concentrated exposure to the specific companies (SpaceX, OpenAI, Anthropic) driving search interest. Treat this as a thematic bet on late-stage technology, not a targeted position in individual names.

Availability: Fundrise.com directly. No brokerage integration required.

Option 4: Public Companies with Material OpenAI / Anthropic Exposure

For non-accredited investors who want indirect exposure through public market vehicles, several public companies have material commercial or strategic relationships with the 2026 IPO cohort:

Microsoft (MSFT): Invested $13+ billion in OpenAI and integrates OpenAI models across its entire product suite (Azure, Office, Copilot). Microsoft's revenue is directly tied to OpenAI's enterprise adoption. It's not a pure OpenAI play, but OpenAI's success is material to Microsoft's growth trajectory.

Google / Alphabet (GOOGL): Has invested heavily in Anthropic (one of Anthropic's largest investors) and competes with OpenAI through Google DeepMind and Gemini. Alphabet has both a strategic investment in Anthropic and a competitive AI product — it's an indirect Anthropic play that's also hedged.

NVIDIA (NVDA): The GPU infrastructure that powers SpaceX, OpenAI, Anthropic, and Databricks training and inference runs predominantly on NVIDIA hardware. NVIDIA doesn't hold equity in any of these companies, but its revenue is directly correlated with their compute spending.

Amazon (AMZN): AWS is the primary cloud infrastructure for Anthropic and a significant OpenAI infrastructure provider. Amazon has also made substantial direct investments in Anthropic. Amazon's AI services revenue is linked to Claude's enterprise deployment.

These are not pre-IPO plays — they're public market proxies. But for non-accredited investors who want exposure to the AI infrastructure and AI model layer without private market complexity, they represent legitimate alternatives.

Option 5: Wait for the IPO

This isn't a workaround — it's a strategy. SpaceX is pricing in June 2026. Anthropic is targeting October 2026. OpenAI is targeting late 2026 or 2027. Databricks is expected to file an S-1 in H2 2026.

When these companies go public, every investor with a brokerage account will have access to shares — without secondary market premiums, ROFR risk, lock-up uncertainty, or unauthorized transfer concerns. The tradeoff is that IPO shares price at the offering price, which may be higher than current secondary market values.

IPO allocation: Most retail investors will not receive IPO allocation at the offering price. IPO shares are allocated primarily to institutional investors. Retail investors typically buy in the open market on or after the first trading day — often at prices above the IPO price.

Lock-up expiration: Even accredited investors holding pre-IPO shares face a 180-day lock-up after the IPO. Post-lock-up sales from insiders and pre-IPO investors often create downward price pressure. Buying in the open market after lock-up expiration (approximately 6 months post-IPO) can sometimes offer a more favorable entry point than buying at IPO.

What to Avoid: Tokenized Pre-IPO Products

In May 2026, both OpenAI and Anthropic issued explicit warnings about tokenized products on blockchain platforms (primarily Solana) claiming to offer pre-IPO exposure. These products — sold by platforms like PreStocks — claimed to hold company shares through SPVs and issue tokens representing economic rights.

Both companies declared all such unauthorized transfers void. Investors holding these tokens have no recognized claim on the company's equity. When the warnings were issued, these tokens plunged approximately 40% immediately.

Rule for non-accredited investors: The fact that a product is accessible to non-accredited investors does not mean it's legitimate. Unauthorized tokenized pre-IPO products are both legally void and often operate in regulatory gray zones. DXYZ, ARKVX, and Fundrise are regulated vehicles with SEC oversight. Solana-based pre-IPO tokens are not.

Summary: Non-Accredited Investor Options Ranked

The Accreditation Path: Worth Considering

If you're close to the accreditation threshold — $200,000 individual income, $300,000 joint, or $1 million net worth excluding primary residence — it's worth evaluating whether qualifying opens meaningfully better access.

For most individual investors approaching accreditation thresholds, the direct secondary market minimums ($25,000–$100,000+) are still significant. The real value of accredited investor status in this context is access to SPVs at $25,000–$50,000 minimums — a meaningful but not transformative improvement over ARKVX or DXYZ for smaller investors.

The 2020 SEC amendments also expanded accreditation to holders of Series 7, 65, or 82 licenses — a professional path that doesn't require any wealth threshold. If you hold one of these licenses, you already qualify.

Where Allocations Fits In

Allocations is accredited-investor-facing infrastructure — it's where GPs build the SPVs and funds that accredited investors invest through. For non-accredited investors, Allocations isn't a direct access point.

What Allocations does do: ensure that the SPVs and funds built on the platform are compliantly formed with proper KYC/AML verification, subscription management, and investor qualification checks. When an accredited investor uses an Allocations-powered vehicle, the compliance infrastructure is institutional-grade — which benefits the overall market integrity that DXYZ and ARKVX also operate within.

Frequently Asked Questions

Can non-accredited investors buy SpaceX stock? Not directly before the IPO. DXYZ (NYSE: DXYZ) holds SpaceX and is accessible through any brokerage account — but typically trades at a premium to NAV. Once SpaceX IPOs, shares will be available to all investors through any brokerage account.

Is DXYZ a good investment? DXYZ provides legitimate pre-IPO exposure to SpaceX, OpenAI, Anthropic, and others, but the NAV premium risk is significant. At a 100%+ premium to NAV, you're paying twice the underlying value of the holdings. Monitor the premium carefully — it can compress quickly when IPOs remove the scarcity dynamic.

When can I buy SpaceX stock directly? SpaceX's S-1 is filed as of mid-2026 with pricing expected mid-June 2026. After the IPO and 180-day lock-up, all investors can buy and sell SpaceX shares through standard brokerage accounts.

Are there any risks to ARKVX? ARKVX is an interval fund with quarterly liquidity gates — you may not be able to redeem immediately if you need capital. The 2.75% management fee is a meaningful annual drag on long-hold returns. And diversified exposure means you're not making a targeted bet on any single company.